Monopost (Latanoprost)

Latanoprost, the active ingredient in Monopost, is a prostaglandin analog presented as an ocular solution (eye drops) for ocular use. It treats primary open‑angle glaucoma and ocular hypertension in adults. GNH USA supplies Monopost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Latanoprost is a prostaglandin analog used to lower intra‑ocular pressure in glaucoma‑related conditions.

Primary open‑angle glaucoma: reduces intra‑ocular pressure to slow disease progression. Ocular hypertension: lowers eye pressure to prevent development of glaucoma. Pseudoexfoliative glaucoma: decreases intra‑ocular pressure to protect optic nerve health.

Latanoprost may cause ocular and peri‑ocular reactions, most of which are mild and reversible.

Common Side Effects: - Eye redness - Eye itching or irritation - Increased eyelash growth - Darkening of the iris - Eye discomfort or foreign‑body sensation - Transient blurred vision

Serious or Rare Side Effects: - Uveitis or intra‑ocular inflammation - Severe eye pain - Sudden vision loss - Allergic contact dermatitis of the eyelid - Periorbital skin hyperpigmentation - Macular edema, especially in patients with pre‑existing retinal disease

Before using Monopost, consider the following safety measures.

Pregnancy: safety not established; avoid unless clearly needed. Breastfeeding: unknown; weigh potential risks and benefits. Contraindications: active ocular infection or inflammation. Monitoring: measure intra‑ocular pressure after initiation and periodically thereafter. Contact lens use: remove lenses before instillation and wait before reinserting. Store at ambient temperature: keep bottle in original container, protect from light and moisture.

Latanoprost can interact with other ocular or systemic agents; review patient medication lists.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory eye drops: may reduce latanoprost efficacy. - Systemic prostaglandin analogs: additive IOP‑lowering effect may cause hypotony. - Carbonic anhydrase inhibitor eye drops: increased risk of ocular side effects.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: additive IOP reduction, monitor pressure. - Alpha‑agonist eye drops: potential enhanced pressure lowering, observe response. - Anticholinergic agents: may affect ocular surface tolerance.